Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa (EASE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03068780
Recruitment Status : Active, not recruiting
First Posted : March 3, 2017
Last Update Posted : March 17, 2022
Sponsor:
Information provided by (Responsible Party):
Amryt Pharma ( Amryt Research Limited )

Tracking Information
First Submitted Date  ICMJE February 27, 2017
First Posted Date  ICMJE March 3, 2017
Last Update Posted Date March 17, 2022
Actual Study Start Date  ICMJE March 29, 2017
Actual Primary Completion Date June 11, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 9, 2020)
Proportion of patients with first complete closure of the EB target wound within 45 days of treatment [ Time Frame: 45±7 days ]
Proportion of patients with first complete closure of the EB target wound (defined as EB partial thickness wound of 10 cm2 to 50 cm2 in size aged ≥ 21 days and < 9 months) in patients with inherited EB (subtypes JEB, DEB, or Kindler syndrome) within 45±7 days of treatment with Oleogel S10 compared to vehicle based on clinical assessment by the investigator (the wound will be rated as "closed" at first appearance of complete reepithelialisation without drainage)
Original Primary Outcome Measures  ICMJE
 (submitted: February 27, 2017)
Proportion of patients with first complete closure of the EB target wound within 45 days of treatment [ Time Frame: 45±7 days ]
Proportion of patients with first complete closure of the EB target wound (defined as EB partial thickness wound of 10 cm² to 50 cm² in size aged ≥21 days) within 45±7 days of treatment with Oleogel-S10 compared to placebo based on clinical assessment by the investigator (the wound will be rated as "closed" at first appearance of complete reepithelialisation without drainage confirmed by a second observation within the following week)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 9, 2020)
  • Time to first complete closure of the EB target wound as evidenced by clinical assessment until EDBP (D90±7) [ Time Frame: 90±7 days ]
  • Proportion of patients with first complete closure of the EB target wound at D90±7 based on clinical assessment by the investigator until Day 90±7. [ Time Frame: 90±7 days ]
  • The incidence of wound infection between baseline (DBP D0) and D90±7 as evidenced by AEs and/or use of topical and/or systemic antibiotics (related to wound infection) [ Time Frame: 90±7 days ]
  • The maximum severity of wound infection between baseline (DBP D0) and D90±7 as evidenced by AEs and/or use of topical and/or systemic antibiotics (related to wound infection) [ Time Frame: 90±7 days ]
  • Change from baseline (DBP D0) in total body wound burden as evidenced by clinical assessment using Section I (assessment of the skin except for the anogenital region) of the 'EB Disease Activity and Scarring Index' (EBDASI) at D90±7 [ Time Frame: 90±7 days ]
  • Change from baseline (DBP D0) in itching using the 'Itch Man Scale' in patients ≥ 4 years and up to 13 years of age and the 'Leuven Itch Scale' in patients ≥ 14 years of age before wound dressing changes at D90±7 [ Time Frame: 90±7 days ]
Original Secondary Outcome Measures  ICMJE
 (submitted: February 27, 2017)
Time to first complete closure of the EB target wound as evidenced by clinical assessment until Day 90±7. [ Time Frame: 90±7 days ]
Time to first complete closure of the EB target wound (defined as EB partial thickness wound of 10 cm² to 50 cm² in size aged ≥21 days) within 90±7 days of treatment with Oleogel-S10 compared to placebo based on clinical assessment by the investigator (the wound will be rated as "closed" at first appearance of complete reepithelialisation without drainage confirmed by a second observation within the following week)
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
Official Title  ICMJE Double Blind, Randomised, Vehicle Controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa
Brief Summary

This is a Phase III, Efficacy and Safety Study of Oleogel-S10 in Participants with Inherited Epidermolysis Bullosa (EB).

EB is a rare group of genetic skin fragility disorders characterised by blistering of the skin in response to minor injury. In most cases, onset of EB is at birth or shortly after. All participants affected by any type of EB share the main characteristic of repeatedly developing painful wounds that take days to months to heal. Current treatment of EB is primarily preventative and supportive including protection from mechanical forces by avoiding rubbing, early treatment of wounds to prevent infections, and protection of the wound with adequate non-adhesive dressings to enable healing.

Oleogel-S10 was authorised in 2016 in the European Union for treatment of partial thickness wounds in adults under the brand name Episalvan®. The active pharmaceutical ingredient in Oleogel-S10 is a refined birch bark extract, quantified to 72 to 88% betulin.

This clinical study of Oleogel-S10 in patients with inherited EB has been initiated to investigate whether Oleogel-S10 is effective for treatment of EB wounds and safe in the long term use.

Oleogel-S10 will be compared to a control gel. The control gel is an identical looking sunflower oil gel that does not contain any active substance. The participant will receive either Oleogel-S10 or control gel for a double-blind study phase of 90 days. The probability that the participant will receive Oleogel-S10 is 50%, which means that they have a 1 in 2 chance of receiving Oleogel-S10. However, in the follow-up phase of the study all participants will be treated with Oleogel S10 for a period of 24 months.

This clinical study will be performed in several countries; in total, about 250 participants are expected to participate.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Epidermolysis Bullosa
Intervention  ICMJE
  • Drug: Oleogel-S10
    10% birch bark extract in 90% sunflower oil
    Other Name: Episalvan
  • Drug: Control gel
    Sunflower oil gel
    Other Name: Vehicle gel
Study Arms  ICMJE
  • Experimental: Oleogel-S10
    Intervention: Drug: Oleogel-S10
  • Placebo Comparator: Control Gel
    Intervention: Drug: Control gel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: November 9, 2020)
223
Original Estimated Enrollment  ICMJE
 (submitted: February 27, 2017)
164
Estimated Study Completion Date  ICMJE July 2022
Actual Primary Completion Date June 11, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and female patients with the following subtypes of inherited EB: junctional EB (JEB), dystrophic EB (DEB), and Kindler syndrome aged ≥21 days,
  • Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm² to 50 cm² in size aged ≥21 days and <9 months),
  • Patient and/or his/her legal representative has/have been informed, has/have read and understood the patient information/informed consent form, and has/have given written informed consent,
  • Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions.

Exclusion Criteria:

  • Patient has EB simplex
  • EB target wound with clinical signs of local infection,
  • Use of systemic antibiotics for wound-related infections within 7 days prior to enrolment,
  • Administration of systemic or topical steroids (except for inhaled, ophthalmic or topical applications, such as budesonide suspension for oesophageal strictures [e.g., Pulmicort respules® 0.25 mg/2 mL or 0.5 mg/2 mL]) within 30 days before enrolment,
  • Immunosuppressive therapy or cytotoxic chemotherapy within 60 days prior to enrolment,
  • Patient has undergone stem cell transplant or gene therapy for the treatment of inherited EB,
  • Current and/or former malignancy including basal cell carcinomas and squamous cell carcinomas,
  • Enrolment in any interventional study or treated with any investigational drug for any disease within 4 weeks prior to study entry,
  • Factors present in the patient and/or his/her legal representative that could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes,
  • Pregnant or nursing women and women of childbearing potential including postmenarchal female adolescents not willing to use an effective form of birth control with failure rates <1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomised partner) during participation in the study (and at least 3 months thereafter),
  • Patient is a member of the investigational team or his/her immediate family,
  • Patient lives in the same household as a study participant.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE Child, Adult, Older Adult
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Austria,   Brazil,   Chile,   Colombia,   Czechia,   Denmark,   France,   Georgia,   Germany,   Greece,   Hong Kong,   Hungary,   Ireland,   Israel,   Italy,   Romania,   Russian Federation,   Serbia,   Singapore,   Spain,   Switzerland,   Ukraine,   United Kingdom,   United States
Removed Location Countries Belgium,   Croatia
 
Administrative Information
NCT Number  ICMJE NCT03068780
Other Study ID Numbers  ICMJE BEB-13
2016-002066-32 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Amryt Pharma ( Amryt Research Limited )
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Amryt Research Limited
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Johannes S Kern, MD PhD Melbourne Health
PRS Account Amryt Pharma
Verification Date March 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP